Advertisement

Breast Cancer Research and Treatment

, Volume 1, Issue 4, pp 287–296 | Cite as

Corpus luteum dysfunction and the epidemiology of breast cancer: A reconsideration

  • Barry M. Sherman
  • Robert B. Wallace
  • Stanley G. Korenman
Review

Summary

Many of the epidemiologic risk factors for the development of breast cancer are related to major events in the female reproductive experience. Several years ago, in an attempt to synthesize these observations, we proposed a theory that focused on abnormal corpus luteum function as a major endocrine determinant of breast cancer risk. This review summarizes the work that has been done attempting to substantiate or refute that hypothesis and reconsiders it in the light of more recent information.

Keywords

breast cancer corpus luteum epidemiology estrogen menstrual cycle progesterone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sherman BM, Korenman SG: Inadequate corpus luteum function: a pathophysiological interpretation of human breast cancer epidemiology. Cancer 33:1306–1312, 1974PubMedGoogle Scholar
  2. 2.
    Kelsey JL: A review of the epidemiology of human breast cancer. Epidemiologic Reviews 1:74–109, 1979PubMedGoogle Scholar
  3. 3.
    Farewell VT, Math B, Math M: The combined effect of breast cancer risk factors. Cancer 40:931–936, 1977PubMedGoogle Scholar
  4. 4.
    Sherman BM, Wallace R, Bean J, Schlabaugh L: Relationship of body weight to menarcheal and menopausal age: implications for breast cancer risk. J Clin Endocrinol Metab 52:488–493, 1981PubMedGoogle Scholar
  5. 5.
    Sherman BM, Korenman SG: Measurement of plasma LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the short luteal phase. J Clin Endocrinol Metab 38:89–93, 1974PubMedGoogle Scholar
  6. 6.
    Sherman BM, Korenman SG: Measurement of serum LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the inadequate luteal phase. J Clin Endocrinol Metab 39:145–149, 1974PubMedGoogle Scholar
  7. 7.
    Sherman BM, Korenman SG: Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 55:699–706, 1975PubMedGoogle Scholar
  8. 8.
    Vollman RF: The Menstrual Cycle, Volume 7. W.B. Saunders Co, Philadelphia, 1977Google Scholar
  9. 9.
    Treloar AE, Boynton RE, Behn BG, Brown BW: Variation of the human menstrual cycle through reproductive life. Int J Fertil 12:77–126, 1967PubMedGoogle Scholar
  10. 10.
    Jones GS, Madrigal-Castro V: Hormonal findings in association with abnormal corpus luteum function in the human: the luteal phase defect. Fertil Steril 21:1–13, 1970PubMedGoogle Scholar
  11. 11.
    Hartz AJ, Barboriak PN, Wong A, Katayama KP, Rimm AA: The association of obesity with infertility and related menstrual abnormalities in women. Int J Obesity 3:57–73, 1979Google Scholar
  12. 12.
    Bulbrook RD, Hayward JL, Spicer CC, Thomas BS: Urinary steroid excretion of normal women and women with advanced breast cancer. Lancet ii:1235–1240, 1962Google Scholar
  13. 13.
    Bulbrook RD, Hayward JL, Thomas BS: The relation between urinary 17-hydroxycorticosteroids and 11-deoxy-17 oxosteroids and the fate of patients with mastectomy. Lancet i:945–947, 1964Google Scholar
  14. 14.
    Bulbrook RD, Hayward JL, Spicer CC: Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet ii:395–398, 1971Google Scholar
  15. 15.
    Abraham GE, Lobotsky J, Lloyd CW: Metabolism of testosterone and androstenedione in normal and ovariectomized women. J Clin Invest 48:696–703, 1969PubMedGoogle Scholar
  16. 16.
    Horwitz KD, McGuire WL: Estrogen control of progesterone receptor in human breast cancer. J Biol Chem 253:2223–2228, 1978PubMedGoogle Scholar
  17. 17.
    Hsueh AJW, Peck EJ Jr, Clark JH: Progesterone antagonism of the estrogen receptor and estrogen-induced uterine growth. Nature 254:337–339, 1975PubMedGoogle Scholar
  18. 18.
    Bhakoo HS, Katzenellenbogen BS: Progesterone inhibition of estrogen-stimulated uterine biosynthetic events and estrogen receptor levels. Mol Cell Endocrinol 8: 121, 1977PubMedGoogle Scholar
  19. 19.
    Haug E: Progesterone suppression of estrogen-stimulated prolactin secretion and estrogen receptor levels in rat pituitary cells. Endocrinology 104:429–437, 1979PubMedGoogle Scholar
  20. 20.
    Labrie F, Ferland L, DiPaulo T, Veilleux R: Modulation of prolactin secretion by sex steroids and thyroid hormones.In RM MacLeod and U Scapagnini (eds): Central and Peripheral Regulation of Prolactin Function. Raven Press, New York, 1980, p 97Google Scholar
  21. 21.
    Tseng L, Gurpide E: Induction of human endometrial estradiol dehydrogenase by progestins. Endocrinology 97:825–833, 1975PubMedGoogle Scholar
  22. 22.
    Pollow K, Lubbert H, Boquoi E, Kreuzer G, Jeske R, Pollow B: Studies on 17 beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma. Acta Endocrinol 79:134–145, 1975PubMedGoogle Scholar
  23. 23.
    Okulicz WC, Evans RW, Leavitt WW: Progesterone regulation of the occupied form of nuclear estrogen receptor. Science 213:1503–1505, 1981PubMedGoogle Scholar
  24. 24.
    Knobil E: The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 36:53–88, 1980PubMedGoogle Scholar
  25. 25.
    Wildt L, Hausler A, Marshall G, Hutchison JS, Plant TM, Belchetz PE, Knobil E: Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. Endocrinology 109:376–385, 1981PubMedGoogle Scholar
  26. 26.
    Richardson DW, Hutchison JS, Pohl CR, Germak JA, Knobil E: Ovarian responses to varying gonadotropic stimuli in the rhesus monkey (abstract). Endocrinology 52: 211, 1981Google Scholar
  27. 27.
    Strott CA, Cargille CM, Ross CT, Lipsett MB: The short luteal phase. J Clin Endocrinol Metab 30:246–251, 1970PubMedGoogle Scholar
  28. 28.
    Knobil E: On the regulation of the primate corpus luteum. Biol Reprod 8:246–258, 1973Google Scholar
  29. 29.
    Halme J, Ikonen M, Rutanen EM, Seppala M: Gonadotropin receptors of human corpus luteum during menstrual cycle and pregnancy. Am J Obstet Gynecol 131: 728–734, 1978PubMedGoogle Scholar
  30. 30.
    Rao CV, Griffen LP, Carman FR: Gonadotropin receptors in human corpora lutea of the menstrual cycle and pregnancy. Am J Obstet Gynecol 128:146–153, 1977PubMedGoogle Scholar
  31. 31.
    Lee CY, Coulam CB, Jiang NS, Ryan RG: Receptors for human luteinizing hormone in human corpora lutea tissue. J Clin Endocrinol Metab 36:148–152, 1973PubMedGoogle Scholar
  32. 32.
    McNatty KP, Sawers RS: Relationship between the endocrine environment within the Graafian follicle and the subsequent rate of progesterone secretion by human granulosa cells in vitro. J Endocrinol 66:391–400, 1975PubMedGoogle Scholar
  33. 33.
    McNatty KP, Smith DM, Makris A, Osathanondh R, Ryan KF: The microenvironment of the human antral follicle: interrelationships among the steroid levels in antral fluid, the population of granulosa cells, and the status of the oocyte in vivo and in vitro. J Clin Endocrinol Metab 49:851–860, 1979PubMedGoogle Scholar
  34. 34.
    Moon YS, Tsang BK, Simpson C, Armstrong DT: Estradiol biosynthesis in cultured granulosa and thecal cells of human ovarian follicles: stimulation by folliclestimulating hormone. J Clin Endocrinol Metab 47:263–267, 1978PubMedGoogle Scholar
  35. 35.
    McNatty KP: Follicular determinants of corpus luteum function in the human ovary.In CP Channing, JM Marsh, WA Sadler (eds): Ovarian Follicular and Corpus Luteum Function. Plenum Press, New York, 1979, p 465Google Scholar
  36. 36.
    Dizerega GS, Hodgen GD: Luteal phase dysfunction infertility: a sequel to aberrant folliculogenesis. Fertil Steril 35:489–499, 1981PubMedGoogle Scholar
  37. 37.
    VanHall EV, Mastboom JL: Luteal phase insufficiency in patients treated with clomiphene. Am J Obstet Gynecol, 103:165–171, 1969PubMedGoogle Scholar
  38. 38.
    Asch RH, Fernandez EO, Siler-Khodr TM, Bartke A, Pauerstein CJ: Mechanism of induction of luteal phase defects by danazol. Am J Obstet Gynecol 136:932–937, 1980PubMedGoogle Scholar
  39. 39.
    Barbieri RL, Osathanondh R, Ryan KJ: Danazol inhibition of steroidogenesis in the human corpus luteum. Obstet Gynecol 57:722–724, 1981PubMedGoogle Scholar
  40. 40.
    Delvoye P, Delogne-Desnoeck J, Robyn C: Hyperprolactinaemia during prolonged lactation: evidence for anovulatory cycles and inadequate corpus luteum. Clin Endocrinol 13:243–247, 1980Google Scholar
  41. 41.
    Dale E, Gerlach DH, Wilhite AL: Menstrual dysfunction in distance runners. Obstet Gynecol 54:47–53, 1979PubMedGoogle Scholar
  42. 42.
    Shangold M, Freeman R, Thysen B, Gatz M: The relationship between long-distance running, plasma progesterone, and luteal phase length. Fertil Steril 31:130–133, 1979PubMedGoogle Scholar
  43. 43.
    Del Pozo E, Wyss H, Tolis G, Alcaniz J, Campana A, Naftolin F: Prolactin and deficient luteal function. Obstet Gynecol 53:282–286, 1979PubMedGoogle Scholar
  44. 44.
    Sarris S, Swyer GIM, McGarrigle HHG, Lawrence DM, Little V, Lachelin GCL: Prolactin and luteal insufficiency. Clin Endocrinol 9:543–547, 1978Google Scholar
  45. 45.
    Radwanska E, Berger GS, Hammond J: Luteal deficiency among women with normal menstrual cycles, requesting reversal of tubal sterilization. Obstet Gynecol 54: 189–192, 1979PubMedGoogle Scholar
  46. 46.
    Donnez J, Wauters M, Thomas K: Luteal function after tubal sterilization. Obstet Gynecol: 57:65–68, 1981PubMedGoogle Scholar
  47. 47.
    Moszkowski E, Woodruff JD, Seegar-Jones GE: The inadequate luteal phase. Am J Obstet Gynecol 83:363–372, 1962PubMedGoogle Scholar
  48. 48.
    Annos T, Thompson IE, Taymor ML: Luteal phase deficiency and interfility: difficulties encountered in diagnosis and treatment. Obstet Gynecol 55:705–710, 1980PubMedGoogle Scholar
  49. 49.
    Davis HH, Simons M, Davis JB: Cystic disease of the breast: Relationship to carcinoma. Cancer 17:957–978, 1964PubMedGoogle Scholar
  50. 50.
    Donnelly PK, Baker KW, Carney JA, Fallon WO: Benign breast lesions and subsequent breast carcinoma in rochester, Minnesota. Mayo Clin Proc 50:650–656, 1975PubMedGoogle Scholar
  51. 51.
    Sitruk-Ware LR, Sterkers N, Mowszowicz I, and Mauvais-Jarvis P: Inadequate corpus luteal function in women with benign breast disease. J Clin Endocrinol Metab 44:771–774, 1977PubMedGoogle Scholar
  52. 52.
    Sitruk-Ware R, Sterkers N, Mauvais-Jarvis P: Benign breast disease I: Hormonal investigation. Obstet Gynecol 53:457–460, 1979PubMedGoogle Scholar
  53. 53.
    Mauvais-Jarvis P, Sitruk-Ware R, Kuttenn F, Sterkers N: Luteal phase insufficiency: a common pathophysiologic factor in development of benign and malignant breast diseases. Commentaries on Research in Breast Disease 1:25–59, 1979Google Scholar
  54. 54.
    Grattarola R: Anovulation and increased androgenic activity as breast cancer risk in women with fibrocystic disease of the breast. Cancer Research 38:3051–3054, 1978PubMedGoogle Scholar
  55. 55.
    England PC, Shenner LG, Cottrell KM, Sellwood RA: Serum oestradiol in women with benign and malignant breast disease. Brit J Cancer 30:571–576, 1974PubMedGoogle Scholar
  56. 56.
    McFadyen IJ, Prescott RJ, Groom GV, Forrest APM, Golder MP, Fahmy DR, Griffiths D: Circulating hormone concentrations in women with breast cancer. Lancet i:1100–1102, 1976Google Scholar
  57. 57.
    Sherman BM, Wallace RB, Jochimsen PR: Hormonal regulation of the menstrual cycle in women with breast cancer: effect of adjuvant chemotherapy. Clin Endocrinol 10:287–296, 1979Google Scholar
  58. 58.
    Kodama M, Kodama T, Miura S, Yoshida M: Hormonal status of breast cancer. III. Further analysis of ovarianadrenal dysfunction. J Natl Cancer Inst 59:49–54, 1977PubMedGoogle Scholar
  59. 59.
    Fishman J, Fukushima D, O'Connor J, Rosenteld RS, Lynch HT, Lynch JF, Guirgis H, Maloney K: Plasma hormone profiles of young women at risk for familial breast cancer. Cancer Res 38:4006–4011, 1978PubMedGoogle Scholar
  60. 60.
    Trichopoulos D, Cole P, Brown JB, Goldman MB, MacMahon B: Estrogen profiles of primiparous and nulliparous women in Athens, Greece. J Natl Can Inst 65:43–46, 1980Google Scholar
  61. 61.
    Bulbrook RD, Moore JW, Clark GMG, Wang DY, Tong D, Hayward JL: Plasma oestradiol and progesterone levels in women with varying degrees of risk of breast cancer. Europ J Cancer 14:1369–1375, 1978Google Scholar
  62. 62.
    Cowan LD, Gordis L, Tonascia JA, Seegar Jones G: Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 114:209–217, 1981PubMedGoogle Scholar
  63. 63.
    Wallace RB, Sherman BM, Bcan JA, Leeper JP, Treloar AE: Menstrual cycle patterns and breast cancer risk factors. Cancer Res 38:4021–4024, 1978PubMedGoogle Scholar
  64. 64.
    Cutler WB, Garcia CR, Krieger AM: Sexual behavior frequency and menstrual cycle length in mature premenopausal women. Psychoneuro-endocrinology 4:297–309, 1979Google Scholar
  65. 65.
    Kelsey J, Lindfors K, White C: A case-control study of the epidemiology of benign breast disease with reference to oral contraceptive use. Int J Epidemiol 3:333–340, 1974PubMedGoogle Scholar
  66. 66.
    Ory H, Colp P, MacMahon B, Hoover R: Oral contraceptives and reduced risk of benign breast diseases. N Engl J Med 294:419–422, 1976PubMedGoogle Scholar
  67. 67.
    Sartwell P, Arthes F, Tonascia J: Epidemiology of benign breast lesions: lack of association with oral contraceptive use. N Engl J Med 288:551–554, 1973PubMedGoogle Scholar
  68. 68.
    Vessey M, Doll R, Sutton P: Oral contraceptives and breast neoplasia: a retrospective study. Brit Med J 3:719–724, 1972PubMedGoogle Scholar
  69. 69.
    Lees AW, Burns PE, Grace M: Oral contraceptives and breast disease in premenopausal northern Albertan women. Int J Cancer 22:700–707, 1978PubMedGoogle Scholar
  70. 70.
    Thomas DB: Role of exogenous female hormones in altering the risk of benign and malignant neoplasms in humans. Cancer Res 38:3991–4000, 1978Google Scholar
  71. 71.
    Janerich DT, Glabatis DM, Dugan JM: Benign breast disease and oral contraceptive use. JAMA 237:2199–2201, 1977PubMedGoogle Scholar
  72. 72.
    Grodin I, Siiteri P, MacDonald P: Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36:207–214, 1973PubMedGoogle Scholar
  73. 73.
    Hosseinian A, Moon HK, Rosenfield RL: Obesity and oligomenorrhea are associated with hyperandrogenism independent of hirsutism. J Clin Endocrinol Metab 42:765–769, 1976PubMedGoogle Scholar
  74. 74.
    Glass A, Swerdloff R, Bray G, Dahms W, Atkinson R: Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab 45: 1211–1219Google Scholar
  75. 75.
    Sonnenschein C, Soto AM: But ⋯ are estrogens per se growth-promoting hormones? J Natl Can Inst 64:211–215, 1980Google Scholar
  76. 76.
    Korenman SG: Oestrogen window hypothesis of the aetiology of breast cancer. Lancet i:700–701, 1980Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1982

Authors and Affiliations

  • Barry M. Sherman
    • 1
  • Robert B. Wallace
    • 1
  • Stanley G. Korenman
    • 2
  1. 1.Departments of Internal Medicine and Preventive MedicineUniversity of Iowa College of MedicineUSA
  2. 2.Department of MedicineUCLA-San Fernando Valley Medical ProgramUSA

Personalised recommendations